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Recent findings in amino acid metabolism and the differences between normal, healthy cells and 
neoplastic cells have revealed that targeting single amino acid metabolic enzymes in cancer therapy is 
a promising strategy for the development of novel therapeutic agents. Arginine is derived from dietary 
protein intake, body protein breakdown, or endogenous de novo arginine production and several studies 
have revealed disturbances in its synthesis and metabolism which could enhance or inhibit tumor cell 
growth. Consequently, there has been an increased interest in the arginine-depleting enzymes and dietary 
deprivation of arginine and its precursors as a potential antineoplastic therapy. This review outlines 
the most recent advances in targeting arginine metabolic pathways in cancer therapy and the different 
chemo- and radio-therapeutic approaches to be co-applied. 
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INTRODUCTION
Certain cancers may be auxotrophic for a particular 
amino acid, and amino acid deprivation is one method to 
treat these tumors. The strategy of enzymatic degradation 
of amino acids to deprive malignant cells of important 
nutrients is an established component of induction therapy 
of several tumor cells. 
The amino acid arginine has considerable nutritional 
and physiological significance as it is recognized as an 
important precursor for the synthesis of proteins, urea, and 
creatine as well as for the synthesis of signaling molecules 
such as glutamate, nitric oxide, and agmatine (Wu, Morris, 
1998). Although arginine is a dispensable (nonessential) 
amino acid for healthy humans, it is conditionally essential 
under certain physiological conditions or disease state 
(Roos, Loos, 1973; Rose, Haines, Warner, 1954; Barbul, 
1986). 
For years, depletion of arginine has been shown to 
be an effective and promising anti-cancer treatment in 
vitro and in vivo (Bach, Swaine, 1965; Wheatley, 2005). 
By culturing cells in the media depleted of arginine, a 
variety of human cancer cells have been found to be 
auxotrophic for arginine, depletion of which results in 
cell death (Tytell, Neuman, 1960; Kraemer, 1964; Dillon 
et al., 2004). Arginine can be degraded by three enzymes: 
arginase, arginine decarboxylase and arginine deiminase 
(ADI). Both arginine decarboxylase and ADI are not 
expressed in mammalian cells (Morris, 2007; Miyazaki 
et al., 1990).
Arginine withdrawal leads to increased protein 
turnover-via reduced synthesis and increased breakdown 
[suppression of mammalian target of rapamycin (mTOR) 
and proteosomal degradation, respectively]-and triggers 
caspase-dependent and caspase-independent apoptotic cell 
death in a cell type-dependent manner (Kim et al., 2009).
This review focus on the recent development of 
targeted therapy of a subset of human malignancies with 
altered arginine metabolism by enzymatic degradation or 
diet restriction. 
Enzymatic degradation of arginine
Arginine deiminase (ADI)
Arginine deiminase (ADI) is a microbial enzyme 
from mycoplasma, it has high affinity to arginine and 
catalyzes arginine to citrulline and ammonia. Citrulline 
can be recycled back to arginine in normal cells which 
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express argininosuccinate synthetase (ASS), whereas 
ASS(-) tumor cells cannot. Loss of ASS expression 
has been most widely associated with melanoma and 
hepatocellular carcinoma, although it has now been 
identified in other tumor types including pancreatic cancer, 
leukemia, prostate cancer and renal cell carcinoma (Gong 
et al., 2000; Ensor et al., 2002; Yoon et al., 2007; Bowles 
et al., 2008; Kim et al., 2009).
As the bacterial enzyme is highly immunogenic 
in humans, therapeutic preparations of ADI have been 
conjugated with polyethylene glycol (20 000 Da; ADI-
PEG20) that serves to reduce the immunogenicity of the 
enzyme while greatly improving its pharmacokinetic half-
life in serum (Feun, Savaraj, 2006; Feun et al., 2008; Ni, 
Schwaneberg, Sun, 2008).
Clinical trials of ADI-PEG20 have been followed 
in both hepatocellular carcinoma and melanoma. 
Pharmacokinetic and pharmacodynamic results from these 
studies demonstrated that a dose of 160 IU m2 ADI-PEG20 
was sufficient to reduce plasma arginine levels from 
~130 μm to below the level of detection (<2 μm) for at least 
7 days (Ascierto et al., 2005; Delman et al., 2005; Izzo et 
al., 2004). However, arginine deprivation can also induce 
ASS expression in certain melanoma cell lines which can 
lead to in vitro drug resistance (Feun et al., 2008).
Acute myeloid leukemia (AML) cells from most 
patients with AML are deficient in ASS1. ADI-PEG 20 
alone induced responses in 19 of 38 AMLs in vitro and 
3 of 6 AMLs in vivo, leading to caspase activation in 
sensitive AMLs. ADI-PEG 20–resistant AMLs showed 
higher relative expression of ASS1 than sensitive AMLs 
(Miraki-Moud et al., 2015). Results also showed that 
the other enzyme in the arginine synthesis pathway, 
argininosuccinate lyase (ASL), was also more highly 
expressed in ADI-PEG 20–resistant AMLs (Miraki-Moud 
et al., 2015). 
Patients with small cell lung cancer (SCLCs) often 
demonstrate a robust initial response to chemotherapy; 
relapse rates remain high, highlighting the need for 
the development of novel therapeutic options in this 
disease. A recent study showed that a large proportion 
of SCLCs lack the expression of ASS, where ~50% of 
human tumors examined were found to lack expression 
of the enzyme (Jungbluth et al., 2010). In vitro studies 
using both adherent and non-adherent ASS-deficient 
SCLC cell lines demonstrated that ADI-PEG20 caused 
dose-dependent anti-proliferative efficacy by inducing 
autophagy, followed by caspase-independent cell death 
(Kelly et al., 2012). Additionally, prolonged treatment 
with ADI-PEG20 may lead to the induction of ASS 
expression and the activation of other cellular pathways 
associated with resistance to apoptosis, possibly limiting 
the overall treatment window for ADI (Kim et al., 2009; 
Tsai et al., 2009). SCLCs xenografts treated continuously 
with 5 IU ADI-PEG20 study demonstrated a sustained 
response to ADI-PEG20 for the 90-day period of the study, 
suggesting that at least at this dose, profound resistance to 
the anti-proliferative effect of ADI-PEG20 had not been 
induced (Kelly et al., 2012). 
ASS1 negativity was detected in 40% of bladder 
cancers as indicated by Allen et al. (2014) ADI-PEG20 
was synthetically lethal in ASS1-methylated bladder cells 
and its exposure was associated with a marked reduction 
in intracellular levels of thymidine, due to suppression of 
both uptake and de novo synthesis. Notably, inhibition 
of de novo synthesis was associated with potentiation of 
ADI-PEG20 activity by the antifolate drug pemetrexed 
(Allen et al., 2014). 
Renal cell carcinoma (RCC) cells treated with ADI 
showed a low expression level of ASS and remarkable 
growth retardation in a dose dependent manner. 
Histological examination of the tumors revealed that 
tumor angiogenesis and vascular endothelial growth factor 
(VEGF) expression were significantly diminished by ADI 
administration (Yoon et al., 2007).
Bowles et al. (2008) evaluated the level of ASS 
expression in 47 human pancreatic adenocarcinoma 
specimens and 20 normal pancreas biopsies. ASS 
expression was not detected in 41 of the 47 (87%) 
pancreatic adenocarcinoma specimens and was observed 
to varying degrees in the non-neoplastic pancreatic ductal 
cells (Bowles et al., 2008). ASS mRNA expression was 
observed at varying levels with L3.3 cell lines having the 
highest level of expression while MIA-PaCa-2 and PANC-
1 having very low levels. All cell lines were subjected to 
increasing doses of PEG-ADI. Cell growth was inhibited 
in MIA-PaCa-2 cells, with an IC50 of 0.3 μg/mL while 
L3.3 cells were unaffected by a broad dose-range of PEG-
ADI. The cytotoxic response of PANC-1 to PEG-ADI 
was very similar to that of MIA-PaCa-2, with the same 
IC50. The growth kinetics of the 3 pancreatic cancer cell 
lines was then examined after ADI treatment (0.3 μg/mL) 
(Bowles et al., 2008). 
It was also observed that the development of 
chemoresistance to platinum compounds in ovarian 
carcinomas leads to collateral appearance of arginine 
auxotrophy due to the downregulation of ASS (Nicholson 
et al., 2009), adding these tumors to the list of potential 
targets of arginine deprivation-based enzymotherapy. 
Arginine deprivation in fact depressed the activation of 
the signaling kinases 4E-BP1 and p70-S6k that govern the 
protein synthesis pathway. These kinases are downstream 
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of mTOR (Hara et al., 1998), which also negatively 
controls autophagy. Shuvayeva et al. (2014) showed that 
combinational treatment based on arginine deprivation 
and an autophagy inhibitor (e.g., chloroquine, a known 
nontoxic antimalarial drug) can potentially be applied as 
a second line treatment for a subset of ovarian carcinomas 
deficient in ASS (Shuvayeva et al., 2014).
Results indicated that ADI-PEG20 can effectively 
induce cell death in prostate cancer cells with low (PC3 
cells) or absent (CWR22Rv1 cells) ASS expression. The 
effect of ADI-PEG20 in CWR22Rv1 mouse xenografts 
reveals reduced tumor activity and reduced tumor 
growth as a monotherapy and in combination with 
chemotherapeutic agents such as docetaxel or autophagy 
inhibitors such as chloroquine. In contrast, LNCaP cells 
highly express ASS and are therefore resistant to both 
ADI-PEG20 and autophagic inhibition (Kim et al., 2009). 
Recombinant human arginase (rhArg)
Recombinant human arginase (rhArg) has been 
developed for arginine deprivation therapy in cancer, 
and is currently under clinical investigation. During 
pre-clinical evaluation, rhArg has exhibited significant 
anti-proliferative activity in cancer cells deficient in the 
expression of ornithine carbamoyl transferase (OCT) 
which metabolizes ornithine and carbamoly phosphate into 
citrulline (Hsueh et al., 2012). OCT is highly expressed in 
liver and small intestine, and catabolizes the conversion 
of ornithine to citrulline (Raijman, 1974). However, OCT 
expression in cancer and other normal tissues is mostly 
down-regulated due to epigenetic changes such as DNA 
hypermethylation (Delers et al., 1984).
Recombinant human arginase (rhArg) demonstrated 
significant cytotoxicity in hepatocellular carcinoma and 
melanoma, in vitro and in vivo (Cheng et al., 2007; Lam 
et al., 2009; Lam et al., 2010). In contrast to ADI-PEG20, 
the sensitivity to rhArg in hepatocellular carcinoma and 
melanoma is independent of ASS expression. 
Quantitative real-time PCR showed minimal to 
absent gene expression of OCT, but ample expression 
of ASS expression in 3 cell lines of in human prostate 
cancer cells: LNCaP (androgen-dependent), PC-3 and 
DU-145 (both androgen-independent). Cell viability assay 
after 72-h exposure of rhArg showed all 3 lines had half 
maximal inhibitory concentration less than or equal to 0.02 
U/ml. Addition of ornithine to cell culture media failed 
to rescue these cells from rhArg-mediated cytotoxicity. 
Decreased phosphorylation of 4E-BP1, a downstream 
effector of mammalian target of rapamycin (mTOR), 
was noted in DU-145 and PC-3 after exposure to rhArg. 
Moreover, there was no significant apoptosis induction 
after arginine deprivation by rhArg in all 3 prostate cancer 
cell lines. In conclusion, rhArg demonstrates a promising 
novel agent for prostate cancer treatment (Cheng et al., 
2007).
To overcome the short circulatory half-life of 
arginase, rhArg(Mn)-PEG5000 was developed and 
investigated with in vivo and in vitro studies in HCC 
(Lam et al., 2010). RhArg(Mn)-PEG5000 was effective 
in inhibiting growth of HCC cell lines as well as 
melanoma cell lines, with IC50 ranging from 0.1–2 IU/
ml. OTC-negative cancer cell lines were more sensitive 
to rhArg(Mn)-PEG5000, while OTC-transfected cell 
lines were resistant. Since some OTC-negative cell lines 
that were sensitive to rhArg(Mn)-PEG5000 had ASS 
expression, this arginase may be an alternative for the 
cancer patient with an ASS-expressing tumor (Yoon et 
al., 2013).
Effectiveness of rhArg was ameliorated by replacing 
the two Mn2+ ions normally present in human arginase I 
with Co2+ resulted in a significantly lowered KM value 
without a concomitant reduction in kcat which increased 
the catalytic efficiency. In addition, the pH dependence 
of the reaction was shifted from a pKa of 8.5 to a pKa of 
7.5 close to the pH of human plasma. Just as important for 
improved efficacy, Co2+ substitution leads to significantly 
increased serum stability of the enzyme (Stone et al., 
2010). In vitro cytotoxicity experiments showed that 
the Co2+ substituted rhArg displays an approximately 
12-15-fold lower IC50 value for the killing of human 
hepatocellular carcinoma Hep3b and melanoma A375 cell 
lines (Stone et al., 2010).
It was also showed that weekly treatment of 8 mg/
kg Co-hArgI-PEG effectively controlled Panc-1 (PC) 
tumor xenografts by inducing autophagy and apoptosis 
in vitro with significant increased expression of activated 
caspase-3 (Glazer et al., 2011). 
Arginine decarboxylase
Arginine decarboxylase (ADC) catalyzes the 
decarboxylation of arginine to agmatine and carbon 
dioxide (Leung, Wei, 2012). So, some researchers 
hypothesize that by applying ADC to the tumor cells, the 
arginine can be depleted and hence the growth of tumor 
cells will be inhibited. Leung and Wei treated colorectal 
cancer cell lines (HCT116 and LoVo) with recombinant 
ADC (rADC) for 72 hours. The anti-proliferation effect 
of rADC was determined by MTT assay and the effect 
of rADC on cell cycle re-distribution and apoptosis was 
analyzed by flow cytometry. Results indicated that rADC 
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exhibited an in vitro anti-proliferation effect on both 
colorectal cell lines tested. Upon treatment with rADC, 
tumor cells were found to arrest at S-phase of the cell 
cycle. rADC also had a potent apoptosis-inducing effect on 
both cell lines. Further studies showed that rADC-induced 
apoptosis was caspase-3 dependent and might follow the 
mitochondrial apoptotic pathway (Leung, Wei, 2012).
Philip, Campbell and Wheatley (2003) tested the 
use of arginine decarboxylase from E. coli in human 
diploid fibroblasts, human uterus HeLa and murine 
leukemia L1210 cells. The response of HeLa to arginine 
decarboxylase was very similar to that seen in fibroblast 
cultures, with good inhibition seen at 1 unit mL−1, but more 
immediate and obvious cell death occurred within 4 days 
with 5 units mL−1. Recovery with citrulline was effective, 
whereas adding arginine to cultures treated with enzymes 
failed to rescue growth because, unlike citrulline, it was 
quickly degraded (Philip, Campbell, Wheatley, 2003). 
L1210 cell line has a considerably higher nutrient demand 
than HeLa cells, and a far greater one than fibroblasts. 
The dose–response curve for arginine decarboxylase 
shows its considerable efficacy against L1210 cells after 
3 days treatment. Most cells were irrecoverable after 
4 days of arginine free medium treatment. A few cells 
persisted, as shown by microscopic examination, these 
being predominantly large multinucleated cells, as seen 
with HeLa cell cultures. Citrulline rescued the cells under 
arginine decarboxylase treatment, but arginine could not 
(Philip, Campbell, Wheatley, 2003). 
While in some respects arginine decarboxylase could 
be an attractive enzyme to use, some problems challenged 
this use. The enzyme produces agmatine which had toxic 
effects when it exceeded millimolar levels in the absence 
of arginine, and therefore some doubt remains as to 
whether a build-up under such conditions is accompanied 
by toxic sequelae in the body. However, agmatine is a 
small molecule that might be quickly cleared but it is also 
known to inhibit nitric oxide synthase and lead to loss of 
vascular tone and signaling in many other vital functions 
(Galea et al., 1996). However, new evidence strongly 
suggests that a special arginine pool may be generated, 
which is closely linked or channeled with nitric oxide 
synthase in appropriate cells (Flam et al., 2001). 
Furthermore, this enzyme requires pyridoxal-5-
phosphate as a cofactor, but in culture researchers have 
found good activity in media where no additional cofactor 
was supplied (Galea et al., 1996). 
In  genera l ,  r ecombinan t  human  a rg in ine 
decarboxylase produced by E. coli is considerably more 
active than enzymes prepared from natural straightforward 
enzyme extraction from other sources, both in vivo and 
in vitro. However, pegylated arginine decarboxylase loses 
almost all its activity, probably because it has far fewer 
lysine residues than arginase. While this will diminish its 
potential use in vivo, this enzyme still requires to be more 
fully evaluated (Philip, Campbell, Wheatley, 2003).
Difluoromethylornithine
Polyamines are organic compounds found in every 
living cell. They are synthesized endogenously from the 
arginine-derived product ornithine which is converted 
by ODC to the diamine putrescine, which is sequentially 
converted into the polyamines spermidine and spermine. 
Polyamines regulate oncogene expression and function 
through transcriptional and posttranscriptional processes 
which implicate a specific link between polyamines and 
cancer (Bachrach, Wang, Tabib, 2001). 
Dietary arginine enhances the risk of APC-
dependent colon carcinogenesis in mouse models by a 
mechanism involving polyamines synthesis. The primary 
consequence of dietary arginine is to increase the adenoma 
grade in these mice. DFMO (difluoromethylornithine), 
an irreversible inhibitor of ornithine decarboxylase, 
inhibits dietary arginine-induced colon carcinogenesis in 
C57BL/6J-ApcMin/J mice by suppressing the arginine-
induced increase in adenoma grade (Gerner, 2007; 
Yerushalmi et al., 2006). 
DFMO has been tested in clinical trials for children 
with neuroblastoma which is the most common solid 
malignancy in children and has generally a poor prognosis. 
Current trial designs include testing lower dose DFMO 
alone (2,000 mg/m2/day) starting at the completion 
of standard therapy, or higher doses combined with 
chemotherapy (up to 9,000 mg/m2/day) for patients with 
relapsed disease that has progressed (Bassiri et al., 2015). 
The findings revealed minimal side effects in patients as 
well three patients with long-term survival. Sholler and 
the Neuroblastoma and Medulloblastoma Translational 
Research Consortium are now testing DFMO in a Phase 
II clinical trial to prevent neuroblastoma relapse (Sholler 
et al., 2015). 
Attenuation of Argininosuccinate Lyase 
The conversion from citrulline to arginine involves 
two enzymes, argininosuccinate synthetase (ASS) and 
argininosuccinate lyase (ASL). ASS seems to be the 
rate-limiting step in the production of arginine (Husson 
et al., 2003), but citrulline availability controls the 
endogenous levels of arginine and NO throughout the body 
(Delage et al., 2010). ASL is transcriptionally induced 
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by endoplasmic reticulum stress and is overexpressed in 
some human liver tumors. Downregulation of ASL by 
short hairpin RNA (shRNA) in three liver cancer cell lines, 
ML-1, HuH-7, and HepG2, decreased colony formation 
in vitro and tumor growth in vivo. The inhibition was 
mainly mediated by a decrease of cyclin A2 and NO 
without altering significantly the total cellular arginine 
level (Huang et al., 2013). 
While exploring the same effect in breast cancer 
tissues, researchers found that ASL was induced by 
endoplasmic reticulum stress and was significantly 
upregulated in breast cancer tissues compared to that in 
the corresponding normal tissues. Downregulation of ASL 
inhibited the growth of breast cancer in vitro and in vivo 
by reducing both cyclin A2 and NO, and delaying G2/M 
transition (Huang et al., 2015). 
Arginine and protein modified diet
Castillo et al. (1994) have studied the changes in 
whole body arginine metabolism over a 6-day arginine-
free diet (Castillo et al., 1994) and extended the period 
of dietary restriction to 4 weeks, including limiting 
the intakes of the major, immediate dietary precursors 
of arginine (glutamate, proline, and aspartate) (Yu et 
al., 2001). In a response to this restriction arginine 
homeostasis is maintained. Results indicate a reduced rate 
of arginine oxidation with maintenance of endogenous 
arginine synthesis, which occurs at a rate of about one-
third of the dietary intake level (Tharakan et al., 2008). 
However, the present diet contained alanine and serine that 
presumably serve as adequate sources of α-amino N. It is 
to be considered that these results can be applied only to 
healthy subjects and with nutritional balance, whereas a 
source of dietary arginine is required in severely stressed 
patients and so in this case arginine is a conditionally 
indispensable amino acid (Yu et al., 2001). Female 
mice with skin carcinogenesis were placed on a special 
synthetic amino acid diet deficient in arginine. This diet 
exhibited a 40–50% reduction in tumor multiplicity and 
had a significantly lower tumor incidence throughout 
a 19-week promotion period. The addition of ornithine 
completely reversed the reduction in the rate and extent 
of tumorigenesis in the arginine-free animals (Gonzalez, 
Byus, 1991).
Dietary restricted protein implies a reduction in 
arginine intake. Fontana et al. (2013) examined the effects 
of isocaloric modifications in dietary protein quantity 
or quality on tumor growth in the human xenograft 
LuCaP23.1, LuCaP35V prostate cancer models and 
WHIM16 breast cancer models. Results showed a 70% 
inhibition of tumor growth in the castrate-resistant 
LuCaP23.1 prostate cancer model and a 56% inhibition in 
the WHIM16 breast cancer model fed with a 7% protein 
diet when compared to an isocaloric 21% protein diet. 
This inhibitory effect was associated with a reduction 
in serum PSA and IGF-1 levels, and a down-regulation 
of intra-tumor mTOR activity in the LuCaP23.1 and 
LuCaP35V models. Protein restriction was also associated 
with modulation of specific histone markers suggesting 
epigenetic modulation (Fontana et al., 2013).
Combination therapies
Although metabolic enzymotherapy based on 
arginine deprivation is considered as nontoxic and 
selective, it is not free of certain limitations. One such 
limitation arises from the upregulation of ASS expression 
in many tumors in response to arginine starvation, leading 
to the appearance of the ASS-positive tumor relapse 
insensitive to the therapy (Vynnytska-Myronovska et 
al., 2012). Also, results showed that tumor cells become 
profoundly more resistant to arginine withdrawal in in 
vitro 3D spheroid models relative to respective monolayer 
cultures (Vynnytska-Myronovska et al., 2013). This 
phenomenon is consistent with the results of animal 
studies and ongoing clinical trials which showed that 
arginine deprivation is effective in inhibiting tumor 
growth but not in inducing tumor regression. The latter 
observation stimulates further search for more efficient 
rational combinational therapeutic approaches based on 
arginine deprivation.
Malignant pleural mesothelioma (MPM) cells do not 
express argininosuccinate synthetase (ASS), and thus are 
vulnerable to ADI-PEG20. Concomitant treatment using 
50 ng/mL of ADI-PEG20 and 10 ng/mL of TNF-related 
apoptosis-inducing ligand (TRAIL) for 24 h resulted in 
profound cell death with 67% of cells positive for caspase-3 
activity, while ADI-PEG20 alone or TRAIL alone resulted 
in only 10-15% cell death. This positive amplification loop 
is mediated through the cleavage of proapototic protein 
“BID” (Wangpaichitr et al., 2014). Savaraj et al. (2010) 
have found that combination of ADI-PEG20 (0.05 μg/
mL) with cisplatin (0.1 μg/mL) can increase apoptosis in 
melanoma cell lines which may be partly due to increase 
in DNA damage (Savaraj et al., 2010). Miraki-Moud et al. 
(2015) showed that the combination of ADI-PEG 20 and 
cytarabine chemotherapy was more effective than either 
treatment alone resulting in responses in all AMLs tested in 
vivo regardless of ASS1 expression (Miraki-Moud et al., 
2015). Interestingly, the addition of 5 uM MEK inhibitor 
(U0126) to 0.06 ug/mL of ADI-PEG20 increased both 
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growth inhibitory effect and apoptosis in the treatment of 
a melanoma cell line, Mel1220. Growth inhibitory effect 
in this combination was 80%, while it was only 15% with 
ADI-PEG20 alone and 25% with U0126 alone. The same 
combination produced 26% of cells which are positive 
for caspase activity and 30% cell death (Savaraj et al., 
2010). Phase I study examined the toxicity and tolerability, 
of weekly intramuscular injection ranging from 4.5–36 
mg/m2 of ADI-PEG 20 in combination with 75 mg/m2 of 
docetaxel every three weeks in patients with advanced 
solid malignancies. ADI-PEG 20 demonstrated reasonable 
toxicity in combination with docetaxel. Arginine was 
variably suppressed with more than half patients achieving 
at least a 50% reduction in baseline values. In 14 patients 
with evaluable disease, four partial responses (including 
two patients with PSA response) were documented and 
seven patients had stable disease (Tomlinson et al., 2015).
Results have shown that the use of rhArg treatment 
resulted in the appearance of autophagosomes and 
upregulation of microtubule-associated protein light chain 
3 II, indicating that rhArg induced autophagy in lymphoma 
cells. So, blocking autophagy using pharmacological 
inhibitors such as 3-methyladenine and chloroquine 
enhanced the cell killing effect of rhArg (Zeng et al., 
2013). 
A new combinatorial metabolic-chemo-radio-
treatment regime was proposed by Vynnytska-Myronovska 
based on arginine starvation, low doses of arginine natural 
analog canavanine and irradiation. Combination treatment 
was remarkably efficient. In particular, pretreatment of 
cancer cells with the arginine-degrading enzyme arginase 
combined with or without low concentration of canavanine 
substantially enhanced cell radioresponse reflected by a 
loss in spheroid regrowth probability and SCD(50) values 
reduced by a factor of 1.5-3 (Vynnytska-Myronovska et al., 
2012). Gong et al. demonstrated that arginine deiminase 
suppresses the growth of unfavorable experimental 
neuroblastomas and that this effect is potentiated by 
irradiation. This combination leads to a reduction in the 
absolute number of tumor vessels and of perfused tumor 
vessels without increasing tumor hypoxia (Gong et al., 
2003). Researchers have evaluated ASS-1 protein pattern 
and the impact of treating 3-D cultures of head and neck 
squamous cell carcinoma (HNSCC) with irradiation under 
arginine-deficient conditions by rh-arginase. Results 
showed that all HNSCC cell lines express ASS-1 protein 
but show different intrinsic levels. Independent of that, 
arginine deprivation leads to an acute cell growth arrest 
in all 2-D and 3-D cultures and only reduced regrowth 
capacity upon completion of the diet in 2-D cultures. 
Similarly, no volume growth during starvation was 
observed for the two 3-D culture models studied. Arginine 
withdrawal resulted in a strong radiosensitization in SAS 
spheroids (Kuo, Savaraj, Feun, 2010).
CONCLUSION
Arginine can be catabolized by three enzymes: 
arginase, arginine decarboxylase and arginine deiminase. 
So the use of these enzymes is a promising procedure for 
arginine enzymatic deprivation as a targeted approach 
to the treatment of certain tumors. Pegylated forms of 
arginine deiminase is used in tumors deficient in ASS, 
while rhArg has exhibited significant anti-proliferative 
activity in cancer cells deficient in the expression of OCT 
which is mostly down-regulated in cancer tissues due 
to epigenetic changes such as DNA hypermethylation. 
Effectiveness of rhArg was ameliorated by replacing 
the two Mn2+ ions normally present in human arginase 
I with Co2+. The anti-proliferation effect of rADC was 
determined in human diploid fibroblasts, human uterus 
HeLa, colorectal and murine leukemia L1210 cells but this 
enzyme still requires to be more fully evaluated.
DFMO (difluoromethylornithine), an irreversible 
inhibitor of ornithine decarboxylase, inhibits polyamines 
synthesis and shows efficacy in colon carcinogenesis and 
neuroblastoma. Furthermore, downregulation of ASL 
inhibited the growth of breast cancer and liver cancer cell 
lines in vitro and in vivo.
The long-term use of ADI-PEG20 treatment 
induces ASS expression in certain melanoma cell lines 
which can lead to in vitro drug resistance. This form of 
resistance may be overcome by using chemo co-applied 
agents such as cytarabine and cisplatin or by the use of 
rhArg as an alternative for the cancer patient with an 
ASS-expressing tumor. Autophagy is the most important 
side effect diminishing the efficacy rhArg which is 
counteracted by the use of pharmacological inhibitors such 
as 3-methyladenine and chloroquine. Many combinatorial 
metabolic-radio-treatment regimens were proposed and 
results showed that arginine withdrawal resulted in a 
strong radiosensitization.
Arginine metabolism differs greatly between healthy 
subjects and stressed patients. It is to be considered that in a 
response to a dietary restriction of arginine, homeostasis is 
maintained in healthy subjects whereas a source of dietary 
arginine is required in severely stressed patients and so in 
this case arginine is a conditionally indispensable amino 
acid. So, dietary restricted protein implies a reduction in 
arginine intake which can be a future prospective method 
used in combination with arginine enzymatic degradation 
for the reduction in the rate and extent of tumorigenesis.
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